The Sepsis Crisis: A Global Health Challenge

Sepsis, a life-threatening condition arising from the body’s dysregulated response to an infection, remains a leading cause of mortality worldwide. According to the World Health Organization, sepsis affects an estimated 49 million people each year, resulting in 11 million deaths. This accounts for a staggering 20% of all global deaths. Within intensive care units (ICUs), sepsis is the number one cause of death, claiming the lives of approximately one-third of affected patients.

Traditionally, sepsis mortality was attributed to an overzealous immune response causing organ damage. However, recent research highlights the critical role of immune system suppression, or “defense paralysis,” in sepsis outcomes. This paralysis leaves patients vulnerable to secondary infections, especially fungal infections, further complicating treatment and increasing mortality rates.

Radboudumc Researchers Uncover a Novel Approach

researchers at Radboud University Medical Center (Radboudumc) in Nijmegen are pioneering a new approach to combat sepsis by focusing on revitalizing the suppressed immune system. Their research, published in Nature immunology, demonstrates that an existing medication, interferon beta, can effectively restore the function of key immune cells compromised during sepsis.

Understanding Immune Response Dynamics

The Radboudumc team, led by IC researcher Guus Leijte, conducted studies involving healthy volunteers. By introducing endotoxins (components of dead bacteria) into the participants’ systems, they were able to simulate a controlled immune response. Using advanced technologies, the researchers meticulously tracked the changes in the immune system during both the initial inflammatory phase and the subsequent phase of immune suppression.

This extensive analysis gave us a better understanding of what happens in an immune response. That gave us starting points for possible treatments with which we can tackle the reduced defense of the body against infections.

farid Keramati, Princess Máxima Center

Monocytes: Key Players in Immune Defense

First author Farid Keramati’s laboratory investigations focused on monocytes, a type of immune cell crucial for fighting infections. His analysis of blood and bone marrow samples from research participants revealed that monocytes become dysfunctional and less effective following the acute inflammatory response.This revelation highlighted a critical mechanism contributing to defense paralysis in sepsis.

Interferon Beta: A Potential Immune System Restorer

The researchers then explored the potential of interferon beta, a medication commonly used to treat multiple sclerosis (MS), to restore monocyte function. In MS, the immune system malfunctions, leading to inflammation in the central nervous system. When interferon beta was introduced to the compromised monocytes in the lab, it had a remarkable effect.

The monocytes were “awakened,” exhibiting improved function and enhanced ability to combat infections. This suggests that interferon beta could potentially reverse the defense paralysis observed in sepsis patients.

Next Steps: From lab to Clinical Request

while these findings are promising, lead researcher Matthijs Kox emphasizes the need for further investigation. The next phase of research will involve administering interferon beta to healthy volunteers in the late phase following endotoxin administration to determine if it can prevent the onset of defense paralysis.

We have now only investigated the functioning of Interferon Bèta in the laboratory on cells. The next step is that we give healthy participants this medicine in the late phase after administration of endotoxins. We want to investigate whether we can prevent the defense paralysis.

Matthijs Kox, Radboudumc

Furthermore, the researchers plan to assess the effectiveness of interferon beta in improving monocyte function in sepsis patients within the ICU setting. If accomplished, this could provide a valuable new tool for treating sepsis and improving patient outcomes. The potential of interferon beta to revitalize the immune system offers a beacon of hope in the ongoing battle against this devastating condition. Future sepsis treatment may include interferon beta.